Akebia Therapeutics Inc at Morgan Stanley Healthcare Conference Transcript
(inaudible) registration desk. So I'd like to welcome to the stage with me from Akebia Therapeutics, CEO, John Butler. I'm one of the analysts here, David Lebowitz. Akebia's a fully integrated nephrology company, which has undergone some change in the last year, certainly with an integration. I guess before we really get started, could you just give a top level overview of the company and where it's come from and where it's going?
Sure, David. First, thanks so much for having us here today. As you said, Akebia is a fully integrated biopharma company that is focused on delivering innovative therapies for patients with kidney disease. And we have a commercial product now in Auryxia with 2 indications, hyperphosphatemia and iron deficiency anemia. And then we have our Phase III product, vadadustat, which is a hypoxia-inducible factor prolyl hydroxylase inhibitor, that's in development for treating the anemia of chronic kidney
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |